Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Merck & Eisai's cancer drug combo shows progress in some but not all key trials for gastroesophageal cancer.

flag Merck & Co. and Eisai's Phase 3 study of Keytruda and Lenvima in gastroesophageal cancer showed a statistically significant improvement in progression-free survival but did not meet the primary endpoint of overall survival. flag The combination treatment's safety profile was consistent with previous studies. flag The drugs are approved for several cancers and are under study for others.

16 Articles